Blood Transfusion Diagnostics Market is Projected to Grow to USD 8,755.2 Million at a CAGR of 6.1% by 2035

The blood transfusion diagnostics market is expected to be worth USD 4,823.4 million by 2025. Fact.MR projects the global market for blood transfusion diagnostics to expand at a CAGR of 6.1% to reach USD 8,755.2 million by 2035. The market is expanding primarily on account of an increasing demand for safe blood screening tests, the increasing prevalence of chronic diseases, and global efforts to improve transfusion-associated healthcare facilities.

Rises in healthcare expenditure in the developing nations, as well as increased realization of transfusion-transmitted diseases (TTDs), are propelling the adoption of robust diagnostic solutions. National blood screening programs are being increasingly sponsored by governments and NGOs, and regulatory authorities are mandating more stringent standards for nucleic acid testing (NAT), antibody screening, and next-generation immunohematology platforms.

For More Insights into the Market, Request a Sample of this Report:
https://www.factmr.com/connectus/sample?flag=S&rep_id=4720

Country-wise Analysis

USA blood transfusion diagnostics market is expected to witness 8.9% CAGR during the forecast period. Sophisticated healthcare setups and highly regulated diagnostic environment make the USA the key driver of innovation in transfusion diagnostics. The prevalence of chronic diseases and surgeries requiring transfusions has raised the demand for accurate, speedy, and effective diagnostic testing.

The UK market for blood transfusion diagnostics will develop at 7.8% CAGR during the period under study. The nation's model of centralized and structured blood services and active government initiatives toward ensuring safety in blood have set a strong foundation for growth in diagnostic gear and test services. Increased focus on supplying a blood supply that is pathogen-free, particularly in the presence of pandemics around the world, is driving investment into transfusion diagnostics.

The South Korean transfusion diagnostics market for blood will grow at a rate of 6.7% CAGR during the study period. Demand growth for transfusion services for chronic diseases and surgery is driving the application of diagnostic equipment to ensure blood safety. Rapid levels of healthcare technology development and sophisticated digital infrastructure in South Korea enable easy adoption of advanced diagnostics in transfusion services.

Segment-wise Analysis

By Product Type

The market of blood transfusion diagnostics is divided by product type into two broad categories: instruments and kits & reagents. The kits and reagents are anticipated to account for 60% of the revenue, and instruments are going to have a 40% share.

By Application

Diagnostics market for blood transfusion is further divided by application into blood grouping and disease screening. Disease Screening is anticipated to account for 50%, and blood grouping is anticipated to achieve a share of 30%.

Competitive Outlook

The market for blood transfusion diagnostics is controlled by a chosen list of strongly specialized firms dealing in serological testing, molecular diagnostics, and automated systems for blood screening. But from 2024 and beyond, competition has made inroads into the requirements of increased automation, improved accuracy, and turnaround time in donor-recipient testing systems.

Major players such as Grifols S.A., Abbott, Ortho Clinical Diagnostics, Bio-Rad Laboratories, Immucor, and Inc. stay ahead in the market with improvement and increase in their immunohematology platforms, strategic acquisition of smaller innovators, and broadening of their assay portfolio.

Grifols S.A. has solidified its global infrastructure in its Procleix NAT (nucleic acid testing) platform that is paired with a partnership link to blood banks globally. Abbott's position still lies in molecular and serological testing with its Alinity and ARCHITECT platforms, which provide improved throughput and greater automation.

Ortho Clinical Diagnostics, which is a part of QuidelOrtho, has been strengthening the foundation acceptance of its VISION platform in Europe and the USA, picking up momentum through scalable solutions in disease-targeted testing.

Browse Full Report: https://www.factmr.com/report/4720/blood-transfusion-diagnostics-market

Key Players

Grifols S.A.
Abbott
Ortho Clinical Diagnostics
Bio-Rad Laboratories, Inc.
Immucor, Inc.
F. Hoffman-La Roche Ltd.
QUOTIENT LIMITED
BAG Healthcare GmBH
DiaSorin S.p.A.
Hologic, Inc.

Segmentation

By Product Type:
Instruments
Kits & Reagents

By Application:
Blood Grouping
Disease Screening
Serological Disease Screening
Molecular Disease Screening

By End-user:
Hospitals
Blood Banks
Diagnostic Laboratories
Plasma Fractionation Companies
Others

By Region:
North America
Europe
Asia Pacific
Latin America
Middle East & Africa

Check out More Related Studies Published by Fact.MR:

Retinal Imaging Devices Market
https://www.factmr.com/report/retinal-imaging-devices-market
Pelvic Floor Electrical Stimulation Devices Market
https://www.factmr.com/report/5245/pelvic-floor-electrical-stimulation-devices-market
Bone Grafts and Substitutes Market
https://www.factmr.com/report/bone-grafts-and-substitutes-market
Blotting Systems Market
https://www.factmr.com/report/blotting-systems-market

Contact:

US Sales Office
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583, +353-1-4434-232
Email: sales@factmr.com

About Fact.MR

We are a trusted research partner of 80% of fortune 1000 companies across the globe. We are consistently growing in the field of market research with more than 1000 reports published every year. The dedicated team of 400-plus analysts and consultants is committed to achieving the utmost level of our client's satisfaction.

This release was published on openPR.